Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

Abstract

The circulating metabolome provides a snapshot of the physiological state of the organism responding to pathogenic challenges. Here we report alterations in the plasma metabolome reflecting the clinical presentation of COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), and critical disease (in intensive care). This analysis revealed major disease- and stage-associated shifts in the metabolome, meaning that at least 77 metabolites including amino acids, lipids, polyamines and sugars, as well as their derivatives, were altered in critical COVID-19 patient’s plasma as compared to mild COVID-19 patients. Among a uniformly moderate cohort of patients who received tocilizumab, only 10 metabolites were different among individuals with a favorable evolution as compared to those who required transfer into the intensive care unit. The elevation of one single metabolite, anthranilic acid, had a poor prognostic value, correlating with the maintenance of high interleukin-10 and -18 levels. Given that products of the kynurenine pathway including anthranilic acid have immunosuppressive properties, we speculate on the therapeutic utility to inhibit the rate-limiting enzymes of this pathway including indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase.

References 39

1. 1.

   Morens DM, Fauci AS. Emerging pandemic diseases: how we got to COVID-19. Cell. 2020;182:1077-1092.

   Not in our library10.1016/j.cell.2020.08.021

2. 2.

   Ghinai I, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020;395:1137-1144.

   Not in our library10.1016/s0140-6736(20)30607-3

3. 3.

   Guan W-J, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708-1720.

   Not in our library10.1056/nejmoa2002032

4. 4.

   Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. New Engl. J. Med. 2020;383:2451-2460.

   Not in our library10.1056/nejmcp2009575

5. 5.

   Petersen E, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect. Dis. 2020;20:e238-e244.

   Not in our library10.1016/s1473-3099(20)30484-9

6. 6.

   Ellinghaus D, et al. Genomewide association study of severe Covid-19 with respiratory failure. N. Engl. J. Med. 2020;383:1522-1534.

   Not in our library10.1056/nejmoa2020283

7. 7.

   Schulte-Schrepping J, et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182:1419-1440.e23.

   Not in our library10.1016/j.cell.2020.08.001

8. 8.

   Silvin, A. et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell182, 1401–1418.e18 (2020).

   Not in our library10.1016/j.cell.2020.08.002

9. 9.

   D’Alessandro A, et al. Serum proteomics in COVID-19 patients: altered coagulation and complement status as a function of IL-6 level. J. Proteome Res. 2020;19:4417-4427.

   Not in our library10.1021/acs.jproteome.0c00365

10. 10.

    Shen B, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182:59-72.e15.

    Not in our library10.1016/j.cell.2020.05.032

11. 11.

    Thomas T, et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI insight. 2020;23:5.

    Not in our library10.1172/jci.insight.140327

12. 12.

    Cai, Y. et al. Kynurenic acid underlies sex-specific immune responses to COVID-19. medRxiv10.1101/2020.09.06.20189159 (2020).

    Not in our library

13. 13.

    Song J-W, et al. Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis. Cell Metab. 2020;32:188-202.e5.

    Not in our library10.1016/j.cmet.2020.06.016

14. 14.

    Sapkota, D., Søland, T. M., Galtung, H. K., Sand, L. P., Giannecchini, S., To, KKW, et al. COVID-19 salivary signature: diagnostic and research opportunities. J. Clin. Pathol.10.1136/jclinpath-2020-206834 (2020).

    Not in our library10.1136/jclinpath-2020-206834

15. 15.

    Steed AL, et al. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science. 2017;357:498-502.

    Not in our library10.1126/science.aam5336

16. 16.

    WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 2020;20:e192-e197.

    Not in our library10.1016/s1473-3099(20)30483-7

17. 17.

    Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72:5435-5440.

    Not in our library10.1158/0008-5472.can-12-0569

18. 18.

    Aslamkhan AG, et al. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice. Toxicol. Appl. Pharmacol. 2020;406:115216.

    Not in our library10.1016/j.taap.2020.115216

19. 19.

    Platten M, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005;310:850-855.

    Not in our library10.1126/science.1117634

20. 20.

    Del Valle DM, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020;26:1636-1643.

    Not in our library10.1038/s41591-020-1051-9

21. 21.

    Grifoni E, et al. Interleukin-6 as prognosticator in patients with COVID-19. J. Infect. 2020;81:452-482.

    Not in our library10.1016/j.jinf.2020.06.008

22. 22.
    Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients · 2020

    No notice
23. 23.

    Laing AG, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 2020;26:1623-1635.

    Not in our library10.1038/s41591-020-1038-6

24. 24.

    Carriche, G. M. et al. Regulating T-cell differentiation through the polyamine spermidine. J. Allergy Clin. Immunol.10.1016/j.jaci.2020.04.037 (2020).

    Not in our library10.1016/j.jaci.2020.04.037

25. 25.

    Madeo, F., Eisenberg, T., Pietrocola, F. & Kroemer, G. Spermidine in health and disease. Science359, eaan2788 (2018).

    Not in our library10.1126/science.aan2788

26. 26.

    Pietrocola F, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell. 2016;30:147-160.

    Not in our library10.1016/j.ccell.2016.05.016

27. 27.
    Polyamines Control eIF5A Hypusination, TFEB Translation, and Autophagy to Reverse B Cell Senescence · 2019

    No notice
28. 28.

    García-Alvarez F, et al. S-adenosylmethionine immunomodulator treatment in sepsis. Int. J. Surg. Investig. 2000;2:9-15.

    Not in our library

29. 29.

    Mehdi A, et al. Enhanced anticancer effect of a combination of S-adenosylmethionine (SAM) and immune checkpoint inhibitor (ICPi) in a syngeneic mouse model of advanced melanoma. Front. Oncol. 2020;10:1361.

    Not in our library10.3389/fonc.2020.01361

30. 30.

    Rosa FT, Freitas EC, Deminice R, Jordão AA, Marchini JS. Oxidative stress and inflammation in obesity after taurine supplementation: a double-blind, placebo-controlled study. Eur. J. Nutr. 2014;53:823-830.

    Not in our library10.1007/s00394-013-0586-7

31. 31.

    Zhang J, Yu M, Tong S, Liu L-Y, Tang L-V. Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan. China J. Clin. Virol. 2020;127:104392.

    Not in our library10.1016/j.jcv.2020.104392

32. 32.

    Steiner J, Bernstein H-G, Guest PC, Summergrad P, Oxenkrug G. Plasma leptin correlates with anthranilic acid in schizophrenia but not in major depressive disorder. Eur. Neuropsychopharmacol. 2020;41:167-168.

    Not in our library10.1016/j.euroneuro.2020.08.001

33. 33.

    Oxenkrug G, van der Hart M, Summergrad P. Elevated anthranilic acid plasma concentrations in type 1 but not type 2 diabetes mellitus. Integr. Mol. Med. 2015;2:365-368.

    Not in our library10.15761/imm.1000169

34. 34.

    Pawlak K, Kowalewska A, Mysliwiec M, Pawlak D. Kynurenine and its metabolites-kynurenic acid and anthranilic acid are associated with soluble endothelial adhesion molecules and oxidative status in patients with chronic kidney disease. Am. J. Med. Sci. 2009;338:293-300.

    Not in our library10.1097/maj.0b013e3181aa30e6

35. 35.

    Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2020;9:1777625.

    Not in our library10.1080/2162402x.2020.1777625

36. 36.

    Liu Q, Hua S, Wang X, Chen F, Gou S. The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma. Cancer Immunol. Immunother. 2021;70:497-508.

    Not in our library10.1007/s00262-020-02697-3

37. 37.

    Pilotte L, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl Acad. Sci. USA. 2012;109:2497-2502.

    Not in our library10.1073/pnas.1113873109

38. 38.

    Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 2017;77:6795-6811.

    Not in our library10.1158/0008-5472.can-17-2285

39. 39.

    Viltard M, et al. The metabolomic signature of extreme longevity: naked mole rats versus mice. Aging. 2019;11:4783-4800.

    Not in our library10.18632/aging.102116

Cited by papers we hold 2

• Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation · 2022
  Not checked
• Signatures of Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of Patients with Post-Acute Sequelae of COVID-19 (PASC) · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.